Abstract:American Journal of HematologyVolume 98, Issue 5 p. E106-E109 CORRESPONDENCEFree Access Ruxolitinib combined with dexamethasone in adult patients with newly diagnosed Hemophagocytic lymphohistiocytosis: A single-center pilot trial De Zhou, De Zhou orcid.org/0000-0002-3698-2750 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXianbo Huang, Xianbo Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorMixue Xie, Mixue Xie Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLixia Zhu, Lixia Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXin Huang, Xin Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXueying Li, Xueying Li orcid.org/0000-0002-9609-1984 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiudi Yang, Xiudi Yang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLi Li, Li Li Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJingjing Zhu, Jingjing Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiaolong Zheng, Xiaolong Zheng Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJianai Sun, Jianai Sun Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorShuqi Zhao, Shuqi Zhao Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWenjuan Yu, Wenjuan Yu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWanzhuo Xie, Wanzhuo Xie orcid.org/0000-0002-0966-5581 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorHongyan Tong, Hongyan Tong orcid.org/0000-0001-5603-4160 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJie Jin, Corresponding Author Jie Jin [email protected] orcid.org/0000-0002-8166-9915 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorHonghu Zhu, Corresponding Author Honghu Zhu [email protected] orcid.org/0000-0003-2343-0436 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorXiujin Ye, Corresponding Author Xiujin Ye [email protected] orcid.org/0000-0002-4553-2751 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], zhuhhd[email protected], [email protected]Search for more papers by this author De Zhou, De Zhou orcid.org/0000-0002-3698-2750 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXianbo Huang, Xianbo Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorMixue Xie, Mixue Xie Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLixia Zhu, Lixia Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXin Huang, Xin Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXueying Li, Xueying Li orcid.org/0000-0002-9609-1984 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiudi Yang, Xiudi Yang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLi Li, Li Li Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJingjing Zhu, Jingjing Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiaolong Zheng, Xiaolong Zheng Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJianai Sun, Jianai Sun Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorShuqi Zhao, Shuqi Zhao Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWenjuan Yu, Wenjuan Yu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWanzhuo Xie, Wanzhuo Xie orcid.org/0000-0002-0966-5581 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorHongyan Tong, Hongyan Tong orcid.org/0000-0001-5603-4160 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJie Jin, Corresponding Author Jie Jin [email protected] orcid.org/0000-0002-8166-9915 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorHonghu Zhu, Corresponding Author Honghu Zhu [email protected] orcid.org/0000-0003-2343-0436 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorXiujin Ye, Corresponding Author Xiujin Ye [email protected] orcid.org/0000-0002-4553-2751 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this author First published: 15 February 2023 https://doi.org/10.1002/ajh.26877 De Zhou, Xianbo Huang and Mixue Xie contributed equally to the work. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL To the Editor: Hemophagocytic lymphohistiocytosis (HLH) is a rapidly progressive and life-threatening disease that can be classified into primary and secondary HLH, most adult patients have secondary HLH, and the main secondary causes are infection, rheumatic disease, and malignancy. The current first-line treatment regimen such as HLH-94 or HLH-2004 are largely extrapolated from pediatric HLH; however, the prognosis of adult HLH is worse than that of children.1, 2 In addition to its unsatisfactory efficacy, the toxicity of HLH-94/HLH-2004 regimens has resulted in relatively high treatment-related mortality,2 Therefore, more efficient and less toxic induction therapy is needed in secondary HLH. Excessive production of cytokines contributes to the pathogenesis of HLH. Recent studies have indicated that ruxolitinib, a small-molecule inhibitor of Janus kinases (JAKs), which are essential for cytokine signaling, may be therapeutic in HLH. A prospective study demonstrated that ruxolitinib is effective and safe in adults with secondary HLH,3 and all patients responded to ruxolitinib and survived for more than two months. Moreover, Lauren K. Meyer et al.4 demonstrated that hypercytokinemia of HLH reduces the apoptotic potential of CD8+ T cells, leading to relative dexamethasone resistance, and this apoptotic potential is restored both in vitro and in vivo upon exposure to ruxolitinib. Based on the above studies, we performed this single-center, pilot study to evaluate the efficacy and tolerability of Ru-D in adult patients with secondary HLH at the First Affiliated Hospital, College of Medicine, Zhejiang University. Patients enrolled in this study met the following criteria: (1) fulfilled at least five of the eight HLH-2004 criteria for HLH; (2) male or female, older than 18 years; (3) no prior chemotherapy treatment for HLH; and (4) signed an informed consent form before participating in the study. Patients who met any one of the following were ineligible: central nervous system involvement, presence of a malignancy, HIV infection, and pregnant women. Patients in this study underwent an 8-week period of treatment. The Ru-D regimen consists of ruxolitinib (15 mg twice daily for 8 weeks) and dexamethasone (initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering). For follow-up and salvage treatment, we employed the following criteria: (1) If patients did not respond to the Ru-D regimen after 7 days or relapsed at any point during treatment, they entered a rescue regimen such as HLH-94 or doxorubicin-etoposide-methylprednisolone (DEP); (2) If patients were diagnosed with lymphoma after enrollment, chemotherapy was immediately started; (3) After 8 weeks of treatment, if no recurrence and no HLH-related gene mutations were detected, treatment was discontinued, and these patients entered the follow-up stage; (4) Allo-HSCT was performed in patients who met the criteria for allo-HSCT. The primary endpoint was the overall response during treatment with the Ru-D regimen in this study. The overall response rate (ORR) included the percentage of patients with a complete response (CR), a partial response (PR), or an improvement in the measures of HLH. Efficacy was evaluated 7, 14, 28, and 56 days after initiating Ru-D therapy. The efficacy of treatment was assessed according to the evaluation criteria proposed by Franco et al5 Secondary endpoints were safety and tolerability, progression-free survival (PFS), overall survival (OS), and changes in biomarkers between baseline and post-treatment. Adverse events in this study were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE 5.0). From April 1, 2021 to May 31, 2021, a total of 8 patients were enrolled in this study. The main clinical characteristics of the patients enrolled are summarized in Table 1. All the patients were adults, and the median age was 48 years (range 23–77 years). Among the 8 patients, five were eventually diagnosed with lymphoma-associated HLH (LAHS) after enrollment. The remaining three included one bacterial infection-associated HLH and two cases of Epstein–Barr virus-associated HLH (EVB-HLH). Serum EBV-DNA copies were positive in seven patients (102–106 copies/mL) and were negative in the patient who was diagnosed with bacterial infection-associated HLH. The eight patients had ECOG performance status scores of 2 to 4, and most patients were steady at 3 or 4. TABLE 1. Baseline characteristics and response of enrolled patients. Clinical features Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Age(years) 37 39 54 69 76 77 42 23 Gender Female Male Male Female Female Female Female Male ECOG score 2 4 3 3 3 3 2 4 Previous therapies IVIG, antibiotics, antivirals, corticosteroid IVIG, antibiotics, corticosteroid Antibiotics, antivirals, corticosteroid Antibiotics, corticosteroid Antibiotics Antibiotics Antibiotics, corticosteroid Antibiotics, corticosteroid Etiology NKTCL Bacterial infections DLBCL PTCL EBV-HLH PTCL EBV-HLH NKTCL Fever Yes Yes Yes Yes Yes Yes Yes Yes Splenomegaly Yes No Yes Yes No No Yes Yes Absolute neutrophil count (×109/L) 1.3 12.07 4.76 0.8 1.7 0.5 0.9 0.6 Hemoglobin concentration (g/L) 77 113 121 82 89 124 81 92 Absolute platelet count (×109/L) 32 282 81 89 67 23 31 3 Triglyceride concentration (mmol/L) 3.14 1.94 2.03 1.06 1.25 3.38 2.31 4.43 Fibrinogen concentration (g/L) 1.05 3.67 6.78 0.96 1.48 1.8 0.5 1.28 Ferritin concentration (μg/L) 1151.8 19176.6 4222.6 2299.4 32847.2 20241.4 5156.3 >40 000 Hemophagocytosis in bone marrow Yes Yes No No Yes Yes Yes Yes Natural killer cell activity (%) 21.05 6.95 14.84 — — — 16.44 14.48 Natural killer cell CD107a (%) 10.44 0.99 3.49 — — — 4.56 1.52 Soluble CD25 (pg/mL) 58 240 20 917 78 770 — — — 13 437 43 403 HLH-2004 criteria 7/8 6/8 5/8 5/8a 5/8a 5/8a 7/8 8/8 EBV-DNA (copies/mL) 3.29 × 106 Negative 9.20 × 102 2.58 × 103 1.23 × 103 9.34 × 102 3.31 × 103 9.47 × 106 Treatment days 26 56 14 52 56 20 56 2 Best Response PR CR Improvement in measures of HLH CR CR PR CR NR Duration of Response (days) 26 269 141 52 244 20 234 — Survival No Yes No No Yes No Yes No Survival time (days) 175 450 141 332 425 20 415 2 Reason for death Progression of lymphoma — CRPA infection Relapse of lymphoma — Bronchiectasis with massive hemoptysis — Progression of HLH Note: Normal reference range: Ferritin concentration < 500 μg/L, Triglyceride concentration 1.70 < mmol/L, Fibrinogen concentration 2.0 ~ 4.0 g/L, soluble CD25 ≤ 6400 pg/mL, soluble CD163 88 ~ 902 pg/mL, Natural killer cell activity≥15.11%, Natural killer cell CD107a ≥ 10%. Abbreviations: CR, complete response; CRPA, carbapenem-resistant pseudomonas aeruginosa; DLBCL, diffuse large B-cell lymphoma; EBV, Epstein–Barr virus; ECOG, Eastern Cooperative Oncology Group; IVIG, intravenous immunoglobulin; NKTCL, NK/T-cell lymphoma; NR, no response; PTCL, peripheral T-cell lymphoma. a Natural killer cell activity and Soluble CD25 were not tested. Patients were followed up until June 30, 2022 or until death, with none lost to follow-up. Table 1 also shows the response outcomes in detail. The median follow-up time was 8.5 (range, 0.1–15.0) months. The ORR to the Ru-D regime was 87.5% (7/8), with 50% (4/8) showing CR, 25.0% (2/8) PR, and 12.5% (1/8) improvement in measures of HLH, 12.5% (1/8) no response (NR). Among the LAHS patients, one patient (20%) achieved CR, two patients (40%) achieved PR, and 1 patient (20%) achieved improvement in measures of HLH, and 1 patient (20%) NR. All the 3 non-LAHS patients achieved CR, and no recurrence has occurred so far. The OS was 75% (6/8) at 2 months, 50% (4/8) at 6 months and 37.5% at 12 months. Although the overall mortality rate was 62.5% (5/8), there was only one death directly related to HLH. The Ru-D treatment in our study was well tolerated, with no toxicities leading to dose reduction or discontinuation of treatment observed. Ruxolitinib has been reported to have a risk of hematological toxicity, which is difficult to evaluate because cytopenia is also the major clinical feature of HLH. We found that only 1 patient (12.5%) had grade III anemia during Ru-D therapy. Four additional patients (50%) developed grade II hematologic toxicity. Regarding infections, pneumocystis pneumonia (PCP) occurred in Patient 7 after 56 days of Ru-D treatment and was successfully cured by trimethoprim-sulfamethoxazole. Patient 6 had a history of baseline bronchiectasis and chronic pulmonary infection with PA before receiving Ru-D. During treatment, this patient suffered aggravation of pulmonary infection and presented with cough, sputum, and inflammatory exudation changes on lung imaging and positive sputum culture for PA, while the body temperature remained within normal limits. She was treated with cefoperazone-sulbactam against PA but had poor control of the infection, developed massive hemoptysis on Day 19, and died in 48 hours. For other patients, no unusual infections were observed. Secondary HLH in adults is a major clinical challenge due to its rapid progression and high mortality. The current first-line treatment strategies are the HLH-94 and HLH-2004 regimens, the ORR was approximately 70%. There were 8 patients enrolled in our study, whose ORR was 87.5%, which is higher than the patients treated with the HLH-94/HLH-2004 regimen. The survival of adult patients with HLH is poor, in a large, multicenter, retrospective study, the median OS in patients with malignancy-associated HLH was 2.8 months and for those with non-malignancy-associated HLH was 10.7 months.3 We also have retrospectively analyzed 205 patients seen between January 2011 and December 2015 in our hospital. The median OS was only 1.8 months, and most of these patients received HLH-94 as initial treatment.6 In this study, the median OS was 4.7 months in patients with LAHS, and all the patients with non-LAHS are now alive with a CR status for more than one year. In contrast to the above studies, this study demonstrated better short-term survival in both malignancy-associated HLH and non-malignancy-associated HLH patients. In our study, Ru-D regimen shows that it is an efficient and safe initial treatment for patients with LAHS, the rapid control of cytokine-driven inflammation gives these patients opportunity to confirm the diagnosis of lymphoma and bridge to chemotherapy. Although Ru-D regimen may improve short-term survival in LAHS patients, their long-term survival remains poor. More effective anti-lymphoma strategies may be the fundamental way to improve the prognosis of these patients. Overall, the Ru-P regimen was well tolerated in this study. Regarding hematologic toxicity, only 1 patient (25%) developed grade III hematologic toxicity. The peripheral blood cell counts of patients who responded gradually improved during Ru-D treatment. However, it should be noted that during Ru-D treatment, we found 2 cases of grade III or higher infection-related AE. Therefore, during Ru-D treatment, we should be aware of the aggravation of the original infection and new opportunistic infections. More experience is needed to assess the need for prophylactic anti-infective therapy in these patients. In summary, this study was a preliminary attempt at giving the Ru-D regimen to newly diagnosed adult HLH patients. Although the sample size was small and the follow-up time was relatively short. Given the rarity and high short-term mortality of adult HLH, the results of this study have some relevance indeed. Ru-D showed a high ORR and good safety and has the potential to become a first-line treatment for HLH in adults. AUTHOR CONTRIBUTIONS De Zhou, Honghu Zhu, Jie Jin, Xiujin Ye, and Xianbo Huang designed the study; De Zhou, Xianbo Huang, and Mixue Xie analyzed the results; De Zhou and Xianbo Huang wrote the paper; De Zhou, Xiu jin Ye, Xianbo Huang, and Xueying Li performed the research; Xin Huang, Xiudi Yang, Li LI, Lixia Zhu, Jingjing Zhu, Xiaolong Zheng, Jianai Sun, Shuqi Zhao, Wenjuan Yu, Wanzhuo Xie, and Hongyan Tong collected the data and reviewed the paper. De Zhou, Xiujin Ye, and Xianbo Huang obtained funding. Honghu Zhu and Jie Jin provided administrative support. All authors read and approved the final manuscript. ACKNOWLEDGMENTS The authors thank the patients and their families, and medical staff who participated in this study. This work was supported by grants from Zhejiang Provincial Natural Science Foundation of China (No. LGF22H160040 and LZ22H080002), and Natural Science Foundation of China (No. 81900152). The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest. Open Research DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. REFERENCES 1Schram AM, Comstock P, Campo M, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. 2016; 172: 412- 419. 2Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002; 100: 2367- 2373. 3Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-Centre, pilot trial. Lancet Haematol. 2019; 6(12):e630-e637. 4Meyer LK, Verbist KC, Albeituni S, et al. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. Blood. 2020; 136(6): 657- 668. 5Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020; 382(19): 1811- 1822. 6Zhou M, Li L, Zhang Q, et al. Clinical features and outcomes in secondary adult hemophagocytic lymphohistiocytosis. Int J Med. 2018; 111: 23- 31. Volume98, Issue5May 2023Pages E106-E109 ReferencesRelatedInformation

Abstract:Clinical and Translational MedicineVolume 13, Issue 4 e824 LETTER TO THE EDITOROpen Access Detection of pathogens and antimicrobial resistance genes directly from urine samples in patients suspected of urinary tract infection by metagenomics nanopore sequencing: A large-scale multi-centre study Manjiao Liu, Manjiao Liu State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. ChinaSearch for more papers by this authorSimin Yang, Simin Yang Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, P. R. ChinaSearch for more papers by this authorSusheng Wu, Susheng Wu State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. ChinaSearch for more papers by this authorLi Chen, Li Chen State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. ChinaSearch for more papers by this authorShan Li, Shan Li State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. ChinaSearch for more papers by this authorZhenzhong Li, Zhenzhong Li State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. ChinaSearch for more papers by this authorMingzhe Zhou, Mingzhe Zhou State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai, P. R. ChinaSearch for more papers by this authorLili Wang, Lili Wang Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, P. R. ChinaSearch for more papers by this authorHui Xu, Hui Xu State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. ChinaSearch for more papers by this authorRyon Liu, Ryon Liu State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. ChinaSearch for more papers by this authorYi Fang, Yi Fang Department of Laboratory Medicine, Huadong Hospital, Fudan University, Shanghai, P. R. ChinaSearch for more papers by this authorWeichun Huang, Weichun Huang Department of Laboratory Medicine, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. ChinaSearch for more papers by this authorMin Zhang, Min Zhang Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, P. R. ChinaSearch for more papers by this authorWenzheng Guo, Wenzheng Guo Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, P. R. ChinaSearch for more papers by this authorYan Dai, Yan Dai State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. ChinaSearch for more papers by this authorYong Ren, Corresponding Author Yong Ren [email protected] State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. China Correspondence Yong Ren and Hao Guo, State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing 210042, P. R. China. Email: [email protected] and [email protected] Wenjuan Wu, Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200123, P. R. China. Email: [email protected]Search for more papers by this authorHao Guo, Corresponding Author Hao Guo [email protected] State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. China Correspondence Yong Ren and Hao Guo, State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing 210042, P. R. China. Email: [email protected] and [email protected] Wenjuan Wu, Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200123, P. R. China. Email: [email protected]Search for more papers by this authorWenjuan Wu, Corresponding Author Wenjuan Wu [email protected] Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, P. R. China Correspondence Yong Ren and Hao Guo, State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing 210042, P. R. China. Email: [email protected] and [email protected] Wenjuan Wu, Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200123, P. R. China. Email: [email protected]Search for more papers by this author Manjiao Liu, Manjiao Liu State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. ChinaSearch for more papers by this authorSimin Yang, Simin Yang Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, P. R. ChinaSearch for more papers by this authorSusheng Wu, Susheng Wu State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. ChinaSearch for more papers by this authorLi Chen, Li Chen State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. ChinaSearch for more papers by this authorShan Li, Shan Li State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. ChinaSearch for more papers by this authorZhenzhong Li, Zhenzhong Li State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. ChinaSearch for more papers by this authorMingzhe Zhou, Mingzhe Zhou State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai, P. R. ChinaSearch for more papers by this authorLili Wang, Lili Wang Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, P. R. ChinaSearch for more papers by this authorHui Xu, Hui Xu State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. ChinaSearch for more papers by this authorRyon Liu, Ryon Liu State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. ChinaSearch for more papers by this authorYi Fang, Yi Fang Department of Laboratory Medicine, Huadong Hospital, Fudan University, Shanghai, P. R. ChinaSearch for more papers by this authorWeichun Huang, Weichun Huang Department of Laboratory Medicine, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. ChinaSearch for more papers by this authorMin Zhang, Min Zhang Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, P. R. ChinaSearch for more papers by this authorWenzheng Guo, Wenzheng Guo Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, P. R. ChinaSearch for more papers by this authorYan Dai, Yan Dai State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. ChinaSearch for more papers by this authorYong Ren, Corresponding Author Yong Ren [email protected] State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. China Correspondence Yong Ren and Hao Guo, State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing 210042, P. R. China. Email: [email protected] and [email protected] Wenjuan Wu, Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200123, P. R. China. Email: [email protected]Search for more papers by this authorHao Guo, Corresponding Author Hao Guo [email protected] State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, P. R. China Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, P. R. China Correspondence Yong Ren and Hao Guo, State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing 210042, P. R. China. Email: [email protected] and [email protected] Wenjuan Wu, Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200123, P. R. China. Email: [email protected]Search for more papers by this authorWenjuan Wu, Corresponding Author Wenjuan Wu [email protected] Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, P. R. China Correspondence Yong Ren and Hao Guo, State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing 210042, P. R. China. Email: [email protected] and [email protected] Wenjuan Wu, Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200123, P. R. China. Email: [email protected]Search for more papers by this author First published: 26 April 2023 https://doi.org/10.1002/ctm2.824 Manjiao Liu, Simin Yang and Susheng Wu contributed equally to this work. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Dear Editor, Previous studies using metagenomics nanopore sequencing to detect pathogens and/or antimicrobial resistant (AMR) genes for urinary tract infection (UTI) had small sample sizes and only focused on UTI caused by bacteria.1, 2 Besides, the bioinformatics pipeline was not optimized. In this study, we optimized the metagenomics nanopore sequencing and bioinformatics pipeline suitable for detecting pathogens and AMR genes from urine samples. We enrolled 1045 samples from four hospitals to assess the pathogen detection, UTI diagnosis and AMR gene detection performance of the pipeline (Figure S1, Tables S1 and S2). We developed the wet-lab pipeline by adjusting the amount of saponin and the PCR system based on a previously published pipeline.3 The limits of detections for three common UTI pathogens were determined using spike-in samples, and precision test results confirmed the stability and repeatability of the methods (Table S3). To accurately detect pathogens and filter out false-positive results, a multi-step workflow using parameters, including blast cut-off, second best match reads ratio, minimal reads and RPK (reads per thousand sequence reads), was proposed (see Supporting Information for detail). We first assessed the performance of nanopore sequencing using 845 samples collected from Shanghai East Hospital. For pathogen detection, we used two reference standards: (1) a clinical culture gold standard and (2) a composite standard incorporated additional results from qPCR. We randomly divided the samples into a training set (n = 199 samples) and a validation set (n = 646 samples). Receiver operator characteristic (ROC) curves were developed at varying RPK values for the training set using the two standards (Figure 1A,B). The ROC curve for training set was used to obtain the optimal thresholds that maximized the Youden index; then the scoring algorithm proposed by Gu4 was used to calculate sensitivity and specificity. In the validation set, using the urine culture standard, the sensitivity for bacterial and fungal detection was 89.8% and 96.3%, respectively; the specificity was 76.9% and 90.1%, respectively (Figure 1C). Using the composite standard, the sensitivity for bacterial and fungal detection was 98.4% and 98.2%, respectively; the specificity for bacterial and fungal detection was 85.4% and 98.1%, respectively (Figure 1C). In all 845 samples, the performance was equivalent to that in the validation set (Figure 1D). A total of 823 samples with clear clinical diagnostic information (758 UTIs and 65 non-UTIs) were used for diagnostic performance assessment (Table S4). Nanopore sequencing obtained a significantly higher sensitivity for UTI diagnosis compared with urine culture (87.86% vs. 81.66%, p < .01), although the specificity was lower than that of urine culture (84.61% vs. 100%, p < .01) (Figure 1E,F). Among the 90 nanopore sequencing false negative samples, 80 samples were weakly positive (pathogen reads were detected but not reached the thresholds), and the remaining 10 samples had few microbial reads (Figure S2A, Table S5). Among 10 nanopore sequencing false-positive samples, 6 samples were likely to reflect latent infections, because they came from patients with risk factors for UTI and clinical symptoms (Figure S2B). Furthermore, the detection frequency of mixed infection in UTI (with two or more organisms) of nanopore sequencing was much higher than that of urine culture (33.51% vs. 5.81%, p < .01) (Figure 1G and Table S6). Subanalysis showed that UTI diagnosis sensitivity and specificity of nanopore sequencing were higher in females compared to males (Figure S3). FIGURE 1Open in figure viewerPowerPoint Pathogen detection and urinary tract infection (UTI) diagnosis performance of nanopore sequencing: (A) receiver operator characteristic (ROC) curves of training set for bacterial and fungal detections using clinical gold standard. Plots show nanopore-sequencing test sensitivity and specificity, relative to the urine culture, at reads per thousand sequence reads (RPK) threshold values ranging from .1 to 1000; (B) ROC curves of training sets for bacterial and fungal detection using composite standard; (C) contingency tables for validation set; (D) contingency tables for all 845 samples; (E) comparison of metagenomics nanopore sequencing and urine culture detection results in UTI and non-UTI groups; (F) contingency tables show the diagnostic performance of urine culture and nanopore sequencing for UTI and non-UTI differentiating. PPV: positive predictive value; NPV: negative predictive value; pos: positive; neg: negative; (G) barplots show the distribution of samples with single organism or two or more organisms detected by culture and metagenomics nanopore sequencing. Next, we validated the pathogen detection performance of metagenomics nanopore sequencing in other three hospitals. For bacteria detection, using composite standard, the sensitivity was 98.9%, 97.6% and 95.4%, respectively; the specificity was 68.3%, 79.7% and 76.3%, respectively (Figure 2). For fungal detection, using composite standard, the sensitivity was 100%, 100% and 85.7%, respectively; the specificity was 96.7%, 98.4% and 97.4%, respectively (Figure 2). The concordance between nanopore sequencing and urine culture in sample level is shown in Figure S4A,B. In samples with inconsistent nanopore sequencing and culture results, concordance between nanopore and qPCR is shown in Figure S4C. FIGURE 2Open in figure viewerPowerPoint Test performance of metagenomics nanopore sequencing in three validation hospitals and all 1045 samples. For comparison in pathogen level, as shown in Figure 3, nanopore sequencing improved the detection of common UTI pathogens, such as Escherichia coli, Enterococcus faecium and Candida albicans, as well as pathogens that are difficult to culture or rare in UTIs, such as Enterococcus hirae5 and Salmonella enterica.6 The most commonly detected pathogens were generally consistent among the four centres and in agreement with previous studies7 (Figure S5). FIGURE 3Open in figure viewerPowerPoint Comparison of nanopore sequencing and urine culture in terms of pathogens. The top 20 frequently detected bacteria and all fungi species detected are listed with their corresponding frequencies plotted in histograms. OR and p values from Fisher's exact test are shown for pathogens with significantly different detection rates between nanopore sequencing and urine culture. We developed an in-house pipeline “NanoAMR” to determine the exact AMR gene subtype. Testing using simulated data showed that when the genomic depth was above 20×; NanoAMR could detect AMR gene subtype accurately (Table S7). Then we performed AMR gene detection in samples with antibiotic susceptibility testing results available. In 239 of 317 samples showed resistance or mediation to at least one type of drug we tested; corresponding resistance genes were detected by nanopore sequencing (Table S8). The incidence of UTIs caused by Enterobacterales species, with extended-spectrum beta-lactamase (ESBL)-positive or carbapenem-resistant (CR) phenotype is increasing and poses a heavy burden on the hospital environment.8, 9 Therefore, we then focused on the detection of genes related to carbapenem resistance and ESBL-positive phenotype in E. coli and Klebsiella pneumoniae (Figure 4). For E. coli, nanopore sequencing detected blaNDM genes in two of three urine samples exhibiting the CR phenotype. Nanopore sequencing detected blaCTX-M genes in 37 of the 43 samples exhibiting ESBL-positive phenotype, most commonly blaCTX-M-14. For K. pneumoniae, in agreement with the phenotypes, blaKPC genes were detected in the six urine samples exhibiting serine enzyme–producing phenotype, and blaNDM-5 was detected in the one urine sample exhibiting MBLs-producing phenotype. BlaSHV or blaCTX-M was detected by nanopore sequencing in all five urine samples exhibiting ESBL-positive phenotype (Figure 4). These results showed that nanopore sequencing could detect the corresponding AMR genes for E. coli and K. pneumoniae exhibiting CR- or ESBL-producing phenotype with high sensitivity, especially for K. pneumoniae, the sensitivity reached 100% in 12 samples (Tables S9 and S10). FIGURE 4Open in figure viewerPowerPoint Detection of beta-lactamase genes related to carbapenem resistance and extended-spectrum beta-lactamase (ESBL)-positive phenotype in Escherichia coli (A) and Klebsiella pneumoniae (B): (A) top panel, results of antibiotic susceptibility tests for cultivated E. coli isolates; bottom panel, beta-lactamase genes distribution in carbapenem-resistant (CR), ESBL-positive (ESBL-pos) and ESBL-negative (ESBL-neg) E. coli groups; (B) top panel, enzyme detection results for cultivated K. pneumoniae isolates; middle panel, results of antibiotic susceptibility tests for cultivated K. pneumoniae isolates; bottom panel, beta-lactamase genes distribution in CR, ESBL-positive (ESBL-pos) and ESBLs-negative (ESBL-neg) K. pneumoniae groups. (A and B) IPM, imipenem; MEM, meropenem; FEP, cefepime; ETP, ertapenem; SCF, cefperazone–sulbactam; CAZ, ceftazidime; CTX, cefotaxime; CRO, ceftriaxone; CXM, cefuroxime; CZO, cephazolin; ATM, aztreonam; TZP, piperacillin–tazobactam; SAM, ampicillin-sulbactam; AMP, ampicillin; PEN, penicillin; CEP, cephalosporin; CAR, carbapenem. In summary, we optimized metagenomics nanopore sequencing and bioinformatics pipeline suitable for detecting pathogens and AMR genes directly from urine samples within 10 h and assessed the performance of the methods in large-scale samples. Notably, in-house bioinformatics pipelines enable AMR gene detection with high sensitivity directly from urine, thus enabling clinicians to adjust antimicrobial therapy in a timely manner. ACKNOWLEDGEMENTS We thank Bo Zheng from Peking University First Hospital to provide part of samples. We thank Shuilian Zhou, Linlin Yan and Bei Zhang for helpful discussions and technical support. CONFLICT OF INTEREST STATEMENT The authors declare no potential conflict of interest. Open Research DATA AVAILABILITY STATEMENT The FASTQ data for this study are available from the corresponding author upon reasonable request. Codes for bioinformatics analysis are available in https://github.com/simceredx22/simNanoUTI. Supporting Information Filename Description ctm2824-sup-0001-SuppMat.docx65.9 KB Supporting Information ctm2824-sup-0002-tables.xlsx483.4 KB Supporting Information ctm2824-sup-0003-figureslegends.docx13.7 KB Supporting Information ctm2824-sup-0004-figureS1.pdf289.2 KB Supporting Information ctm2824-sup-0005-figureS2.pdf176.4 KB Supporting Information ctm2824-sup-0006-figureS3.pdf248.1 KB Supporting Information ctm2824-sup-0007-figureS4.pdf64.2 KB Supporting Information ctm2824-sup-0008-figureS5.pdf216.3 KB Supporting Information ctm2824-sup-0009-figureS6.pdf117.3 KB Supporting Information ctm2824-sup-0010-figureS7.pdf233.5 KB Supporting Information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Schmidt K, Mwaigwisya S, Crossman LC, et al. Identification of bacterial pathogens and antimicrobial resistance directly from clinical urines by nanopore-based metagenomic sequencing. J Antimicrob Chemother. 2017; 72: 104- 114. 2Zhang L, Huang W, Zhang S, et al. Rapid detection of bacterial pathogens and antimicrobial resistance genes in clinical urine samples with urinary tract infection by metagenomic nanopore sequencing. Front Microbiol. 2022; 13:858777. 3Charalampous T, Kay GL, Richardson H, et al. Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection. Nat Biotechnol. 2019; 37: 783- 792. 4Gu W, Deng X, Lee M, et al. Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids. Nat Med. 2021; 27: 115- 124. 5Bilek HC, Deveci A, Unal S, Tanriverdi Cayci Y, Tanyel E. Enterococcus hirae as a cause of bacteremic urinary tract infection: first case report from Turkey. J Infect Dev Ctries. 2020; 14: 1780- 1482. 6Mellon G, Delanoe C, Roux AL, et al. Non-typhi Salmonella enterica urinary tract infections. Med Mal Infect. 2017; 47: 389- 393. 7Neugent ML, Hulyalkar NV, Nguyen VH, Zimmern PE, De Nisco NJ. Advances in understanding the human urinary microbiome and its potential role in urinary tract infection. mBio. 2020; 11: e00218- 20. 8Miftode IL, Nastase EV, Miftode RS, et al. Insights into multidrug-resistant K. pneumoniae urinary tract infections: from susceptibility to mortality. Exp Ther Med. 2021; 22: 1086. 9Karlowsky JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF. Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: sMART 2013–2015. J Med Microbiol. 2017; 66: 61- 69. Volume13, Issue4April 2023e824 FiguresReferencesRelatedInformation

Reporting Assessment of Multicenter Clinical Trial Protocols: A Cross-Sectional Study

Expert Consensus on Perioperative Medications During Endoscopic Submucosal Dissection for Gastric Lesions (2015, Suzhou, China)

Withdrawal: Prospective Randomized Comparison Between Upgraded “2C3L” Versus PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation: PROMPT‐AF Trial Design

Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Single‐center Pilot Trial

Detection of Pathogens and Antimicrobial Resistance Genes Directly from Urine Samples in Patients Suspected of Urinary Tract Infection by Metagenomics Nanopore Sequencing: A Large-Scale Multi-Centre Study

Ndt_a_266642 2419..2428

Prevalence and Risk Factors of Chronic Urticaria in China: A Nationwide Cross‐sectional Study

OEM China Water Storage Bladder Tanks OEM/ODM Quotes - Rongda

The Concentrated Antibody from Convalescent Plasma Balanced the Dysfunctional Immune Responses in Patients with Critical COVID‐19

The Monoamine Oxidase-B Inhibitor Selegiline Does Not Affect 18 F-Florzolotau Uptake in Patients with Progressive Supranuclear Palsy: A Longitudinal Case Series.

Cohort Profile: the Tongji Maternal and Child Health Cohort (TMCHC).

Study protocol: A national cross-sectional study on psychology and behavior investigation of Chinese residents in 2023, PBICR

Focus on China: Should Clinicians Engage in Research? and Lessons from Other Countries.

Sex-specific Characteristics and Outcomes in Hospitalized Heart Failure with Preserved Ejection Fraction: the China Cardiovascular Association Database-Heart Failure Center Registry.

Are medical record front page data suitable for risk adjustment in hospital performance measurement? Development and validation of a risk model of in-hospital mortality after acute myocardial infarction

Developing an Individualized Clinical Prediction Rules of Antihypertensive Drugs: A Study Protocol Based on Real-world Practice

Persistent Viral Activity, Cytokine Storm, and Lung Fibrosis in a Case of Severe COVID‐19

Associations of Tenascin C with Th2 Response, Edema Degree, and Disease Severity in Patients with Chronic Rhinosinusitis with Nasal Polyps.

Cohort Profile: the Shanghai Maternal-Child Pairs Cohort (MCPC).

The Study Design and Methodology of Antibiotic Duration in Hematological Patients with Pseudomonas Aeruginosa Bloodstream Infection.